Virchows Archiv

, Volume 460, Issue 1, pp 3–8 | Cite as

Personalized cancer medicine and the future of pathology

  • H. Moch
  • P. R. Blank
  • M. Dietel
  • G. Elmberger
  • K. M. Kerr
  • J. Palacios
  • F. Penault-Llorca
  • G. Rossi
  • T. D. Szucs
Review and Perspectives

Abstract

In February 2011, a group of pathologists from different departments in Europe met in Zurich, Switzerland, to discuss opportunities and challenges for pathology in the era of personalized medicine. The major topics of the meeting were assessment of the role of pathology in personalized medicine, its future profile among other biomedical disciplines with an interest in personalized medicine as well as the evolution of companion diagnostics. The relevance of novel technologies for genome analysis in clinical practice was discussed. The participants recognize that there should be more initiatives taken by the pathology community in companion diagnostics and in the emerging field of next-generation sequencing and whole genome analysis. The common view of the participants was that the pathology community has to be mobilized for stronger engagement in the future of personalized medicine. Pathologists should be aware of the challenges and the analytical opportunities of the new technologies. Challenges of clinical trial design as well as insurance and reimbursement questions were addressed. The pathology community has the responsibility to lead medical colleagues into embracing this new area of genomic medicine. Without this effort, the discipline of pathology risks losing its key position in molecular tissue diagnostics.

Keywords

Translational research Next-generation sequencing Whole genome analysis Molecular pathology 

Notes

Acknowledgments

We thank Mrs. B. Terrier for support in writing this article. The panel meeting of European pathologists held at the Institute of Surgical Pathology Zurich, Switzerland, was supported by Pfizer Inc.

References

  1. 1.
    Stricker T, Catenacci DV, Seiwert TY (2011) Molecular profiling of cancer—the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 38:173–185PubMedCrossRefGoogle Scholar
  2. 2.
    Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRefGoogle Scholar
  3. 3.
    Alizadeh AA, Eisen MB, Davis RE et al (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511PubMedCrossRefGoogle Scholar
  4. 4.
    Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRefGoogle Scholar
  5. 5.
    Hortobagyi GN (2005) Trastuzumab in the treatment of breast cancer. N Engl J Med 353:1734–1736PubMedCrossRefGoogle Scholar
  6. 6.
    Rubin BP, Heinrich MC, Corless CL (2007) Gastrointestinal stromal tumour. Lancet 369:1731–1741PubMedCrossRefGoogle Scholar
  7. 7.
    Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRefGoogle Scholar
  8. 8.
    Maemondo M, Inoue A, Kobayashi K et al (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2380–2388PubMedCrossRefGoogle Scholar
  9. 9.
    Flaherty KT, Puzanov I, Kim KB et al (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809–819PubMedCrossRefGoogle Scholar
  10. 10.
    Soda M, Choi YL, Enomoto M et al (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–566PubMedCrossRefGoogle Scholar
  11. 11.
    Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634PubMedCrossRefGoogle Scholar
  12. 12.
    Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27:1130–1136PubMedCrossRefGoogle Scholar
  13. 13.
    Gabrielson E, Berg K, Anbazhagan R (2001) Functional genomics, gene arrays, and the future of pathology. Mod Pathol 14:1294–1299PubMedCrossRefGoogle Scholar
  14. 14.
    Anonymous (2011) Getting personal. Nature 473:253–254Google Scholar
  15. 15.
    Luciano JS, Andersson B, Batchelor C et al (2011) The translational medicine ontology and knowledge base: driving personalized medicine by bridging the gap between bench and bedside. J Biomed Semantics 2(Suppl 2):S1PubMedCrossRefGoogle Scholar
  16. 16.
    Dahinden C, Ingold B, Wild P et al (2010) Mining tissue microarray data to uncover combinations of biomarker expression patterns that improve intermediate staging and grading of clear cell renal cell cancer. Clin Cancer Res 16:88–98PubMedCrossRefGoogle Scholar
  17. 17.
    Jones S, Zhang X, Parsons DW et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806PubMedCrossRefGoogle Scholar
  18. 18.
    Carracedo A, Ma L, Teruya-Feldstein J et al (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118:3065–3074PubMedGoogle Scholar
  19. 19.
    Tonellato PJ, Crawford JM, Boguski MS, Saffitz JE (2011) A national agenda for the future of pathology in personalized medicine: report of the proceedings of a meeting at the Banbury Conference Center on genome-era pathology, precision diagnostics, and preemptive care: a stakeholder summit. Am J Clin Pathol 135:668–672PubMedCrossRefGoogle Scholar
  20. 20.
    Salzberg SL, Pertea M (2010) Do-it-yourself genetic testing. Genome Biol 11:404PubMedCrossRefGoogle Scholar
  21. 21.
    Blank PR, Moch H, Szucs TD, Schwenkglenks M (2011) KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective. Clin Cancer Res 17:6338–6346PubMedCrossRefGoogle Scholar
  22. 22.
    Blank PR, Schwenkglenks M, Moch H, Szucs TD (2010) Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies. Breast Cancer Res Treat 124:497–507PubMedCrossRefGoogle Scholar
  23. 23.
    Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826PubMedCrossRefGoogle Scholar
  24. 24.
    Blank PR, Dedes KJ, Szucs TD (2010) Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. PharmacoEconomics 28:629–647PubMedCrossRefGoogle Scholar
  25. 25.
    Roth AD, Tejpar S, Delorenzi M et al (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol 28:466–474PubMedCrossRefGoogle Scholar
  26. 26.
    Palanisamy N, Ateeq B, Kalyana-Sundaram S et al (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793–798PubMedCrossRefGoogle Scholar
  27. 27.
    AMP Whole Genome Analysis Working Group (2011) The Association for Molecular Pathology’s approach to supporting a global agenda to embrace personalized genomic medicine. J Mol Diagn 13:249–251CrossRefGoogle Scholar
  28. 28.
    Dietel M, Sers C (2006) Personalized medicine and development of targeted therapies: the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch 448:744–755PubMedCrossRefGoogle Scholar
  29. 29.
    Pirker R, Herth FJ, Kerr KM et al (2010) Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 5:1706–1713PubMedCrossRefGoogle Scholar
  30. 30.
    Marchetti A, Normanno N, Pinto C et al (2010) Recommendations for mutational analysis of EGFR in lung carcinoma. Pathologica 102:119–126PubMedGoogle Scholar
  31. 31.
    Kulesza P, Ramchandran K, Patel JD (2011) Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol 136:228–238PubMedCrossRefGoogle Scholar
  32. 32.
    van Krieken JH, Jung A, Kirchner T et al (2008) KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program. Virchows Arch 453:417–431PubMedCrossRefGoogle Scholar
  33. 33.
    Macconaill LE, Van Hummelen P, Meyerson M, Hahn WC (2011) Clinical implementation of comprehensive strategies to characterize cancer genomes: opportunities and challenges. Cancer Discov 1:297PubMedCrossRefGoogle Scholar
  34. 34.
    Cagle PT, Allen TC, Dacic S et al (2011) Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 135:110–116PubMedGoogle Scholar
  35. 35.
    Kerr K (2011) Personalized medicine for lung cancer: new challenges for pathology. Histopathology. doi: 10.1111/j.1365-2559.2011.03854.x

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • H. Moch
    • 1
  • P. R. Blank
    • 2
  • M. Dietel
    • 3
  • G. Elmberger
    • 4
  • K. M. Kerr
    • 5
  • J. Palacios
    • 6
  • F. Penault-Llorca
    • 7
  • G. Rossi
    • 8
  • T. D. Szucs
    • 9
  1. 1.Institute of Surgical PathologyUniversity Hospital ZurichZurichSwitzerland
  2. 2.Institute of Social and Preventive MedicineUniversity of ZurichZurichSwitzerland
  3. 3.Institute of PathologyUniversity Hospital CharitéBerlinGermany
  4. 4.Department of PathologyKarolinska University HospitalStockholmSweden
  5. 5.Department of PathologyAberdeen Royal Infirmary & Aberdeen University Medical SchoolAberdeenUK
  6. 6.Department of PathologyHospital Universitario Virgen del Rocío/Instituto de Investigacions Biomédicas (IBIS) SevillaSevillaSpain
  7. 7.Department of PathologyCentre Jean Perrin et Université d’AuvergneClermont-Ferrand CedexFrance
  8. 8.Section of Pathologic AnatomyAzienda Policlinico di ModenaModenaItaly
  9. 9.European Center of Pharmaceutical MedicineUniversity of BaselBaselSwitzerland

Personalised recommendations